Breast Cancer | Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Case: A woman in her late 40s who received treatment for triple-negative breast cancer develops lung metastases 2 years later (0:00) Clinical trials investigating TROP2-targeting antibody-drug conjugates (13:28) Identifying and targeting HER2 in HER2 low-expressing disease (21:17) Case: A woman in her early 50s who received treatment for Stage I breast cancer later develops multiple lesions similar to the original cancer (29:00) Thresholds of HER2 expression and the efficacy of trastuzumab deruxtecan (T-DXd) (34:01) Case: A woman in her late 50s receiving T-DXd for HER2-low metastatic breast cancer develops asymptomatic ground glass infiltrates in the lung (39:19) Novel ADC strategies under investigation (48:22) CME information and select publications